Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients With Type 2 Diabetic Nephropathy

PR Newswire2024/12/19 20:30

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

PR Newswire2024/12/16 20:30

Palatin Technologies Shares Are Trading Higher After the Company Announced the Completion of Enrollment in Its Phase 2 Study of PL8177.

Benzinga2024/11/25 23:42

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

PR Newswire2024/11/25 20:30

Q1 2025 Palatin Technologies Inc Earnings Call

Yahoo Finance2024/11/15 18:24

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript Summary

Futuニュース2024/11/15 02:00